Compare ResMed Inc. (RMD) vs Viasat (VSAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Viasat — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Viasat trades at $72.01 (market cap $10.71B). The key difference: ResMed Inc. is far larger — about 3× Viasat's market cap, and ResMed Inc. pays a 1.19% dividend while Viasat pays none. Which is the better fit depends on your goals.
| RMD | VSAT | |
|---|---|---|
Market Cap | $31.89B | $10.71B |
Sector | Health | Technology |
52-Week High | $283.28 | $89.81 |
52-Week Low | $182.82 | $28.41 |
Enterprise Value | $31.24B | $15.90B |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
VSAT trades at $77.75, up 3.23% today, with a neutral technical signal. The company reported mixed Q2 2026 earnings, missing EPS estimates, but Q1 and Q4 2025 beat expectations. Revenue for 2025 was $4.52B with a net loss of $574.96M, though 2026 projections show improved profitability. Analyst consensus is balanced with 40% buy and 40% hold ratings. Recent news highlights the ViaSat-3 F3 satellite entering service in Asia-Pacific and new government contracts, signaling growth potential in satellite communications.
The outlook for VSAT is cautiously optimistic, driven by satellite deployment and government deals, but execution risks and competition from players like Starlink pose challenges. Investors should weigh the potential for revenue growth and margin improvement against high debt levels and ongoing losses. Near-term price action may hinge on Q3 2026 earnings and ViaSat-3 commercialization progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Viasat
Viasat provides satellite communications and connectivity services for aviation, maritime, government, enterprise, and consumer markets. Its network combines satellite and ground infrastructure to deliver connectivity in remote and mobile environments.
Read more on VSAT →
